Frank Guarnieri

Summary

Publications

  1. doi request reprint Designing a small molecule erythropoietin mimetic
    Frank Guarnieri
    Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Methods Mol Biol 1289:185-210. 2015
  2. doi request reprint Designing an Orally Available Nontoxic p38 Inhibitor with a Fragment-Based Strategy
    Frank Guarnieri
    Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Methods Mol Biol 1289:211-26. 2015
  3. pmc A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema
    Frank Guarnieri
    Paka Pulmonary Pharmaceuticals, Acton, MA 01720, USA
    Proc Natl Acad Sci U S A 107:10661-6. 2010

Detail Information

Publications3

  1. doi request reprint Designing a small molecule erythropoietin mimetic
    Frank Guarnieri
    Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Methods Mol Biol 1289:185-210. 2015
    ..In the second half of the century EPO was discovered and by the end of the century it became a blockbuster commercial product that launched the biotech revolution. ..
  2. doi request reprint Designing an Orally Available Nontoxic p38 Inhibitor with a Fragment-Based Strategy
    Frank Guarnieri
    Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Methods Mol Biol 1289:211-26. 2015
    ..Devoting a large amount of limited resources to a target that ultimately turns out to be a mistake because it was not properly validated is a fatal error for a small company, and this is one of the reasons that Locus ultimately failed. ..
  3. pmc A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema
    Frank Guarnieri
    Paka Pulmonary Pharmaceuticals, Acton, MA 01720, USA
    Proc Natl Acad Sci U S A 107:10661-6. 2010
    ..Covalently combining an endogenous peptide from the target organ with a synthetic small molecule inhibitor is a unique way of endowing an active compound with the pharmacodynamic profile needed to create in vivo efficacy...